News
INM
0.2900
-3.65%
-0.0110
InMed Pharmaceuticals Welcomes Alzheimer’s Expert
TipRanks · 1d ago
InMed Pharmaceuticals Preclinical Success with INM-089
TipRanks · 2d ago
InMed Pharmaceuticals Provides Update On INM-089 In The Treatment Of Dry Age-Related Macular Degeneration; Small Molecule Drug Acting As A Preferential Signaling Ligand For CB1/CB2
Benzinga · 2d ago
INMED PHARMACEUTICALS INC - SMALL MOLECULE DRUG ACTING AS A PREFERENTIAL SIGNALING LIGAND FOR CB1/CB2
Reuters · 2d ago
InMed’s INM-089 Shows Promise for AMD Treatment
TipRanks · 3d ago
Weekly Report: what happened at INM last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at INM last week (0401-0405)?
Weekly Report · 04/08 12:32
InMed Pharmaceuticals Excites with Alzheimer’s Breakthrough
InMed Pharmaceuticals (INM) has revealed promising pre-clinical results for a potential Alzheimer's treatment. The company is working on a new drug called INM-901 to treat Alzheimer's disease. The drug could be a significant step forward in the treatment of the disease.
TipRanks · 04/05 15:42
InMed’s INM-901 Shows Promise Against Alzheimer’s
Inmed Pharmaceuticals Inc. Has announced promising preclinical results for INM-901, a potential treatment for Alzheimer’s disease. The treatment shows reduced neuroinflammation and improved neuronal function. INM is a potential candidate for the treatment of Alzheimer's disease.
TipRanks · 04/04 12:37
Weekly Report: what happened at INM last week (0325-0329)?
Weekly Report · 04/01 12:28
Weekly Report: what happened at INM last week (0318-0322)?
Weekly Report · 03/25 12:32
InMed Pharmaceuticals Granted Nasdaq Compliance Extension
TipRanks · 03/20 17:52
InMed Pharmaceuticals Receives Nasdaq Extension
TipRanks · 03/20 13:08
InMed Pharmaceuticals gets 180-Day extension to regain compliance with Nasdaq
InMed Pharmaceuticals gets 180-Day extension to regain compliance with Nasdaq. The company has been granted an additional 180-day compliance period until September 16, 2024. The Nasdaq has no immediate effect on the listing or trading of the company's shares. Healthcare InMed pharmaceuticals Inc. (INM)
Seeking Alpha · 03/20 12:38
Weekly Report: what happened at INM last week (0311-0315)?
Weekly Report · 03/18 12:30
Weekly Report: what happened at INM last week (0304-0308)?
Weekly Report · 03/11 12:24
InMed Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 16/098,324 Titled "Use Of Topical Formulations Of Cannabinoids In The Treatment Of Epidermolysis Bullosa And Related Connective Tissue Disorders"
Benzinga · 03/07 21:00
Weekly Report: what happened at INM last week (0226-0301)?
Weekly Report · 03/04 12:29
Weekly Report: what happened at INM last week (0219-0223)?
Weekly Report · 02/26 12:50
InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
Dow Jones index closed higher by over 450 points on Thursday. When insiders purchase or sell shares, it indicates confidence or concern around the company's prospects. Recent notable insider transactions for penny stocks include GeoVax Labs, Inc. And InMed Pharmaceuticals Inc. Beneficient director acquired 400,000 shares at an average price of $0.26.
Benzinga · 02/23 12:34
More
Webull provides a variety of real-time INM stock news. You can receive the latest news about Inmed Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About INM
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.